Yea its a really strangely specific flex "largest DFI infection study in the country". Lol!
CYP (stem cells) are currently running a DFI trial targeting 30 patients vs Recce's 32 patients. So pretty mich same size trial, although CYP have more sites. Interestingly, CYP's trial is also moving very slowly. They plan to announce clinical data for their first 16 patients this quarter - will be good to compare notes.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)